Nifty
Sensex
:
:
11810.85
40252.03
43.10 (0.37%)
106.53 (0.27%)

Pharmaceuticals & Drugs

Rating :
62/99  (View)

BSE: 524731 | NSE: Not Listed

356.05
-8.85 (-2.43%)
27-Oct-2020 | 11:20AM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  361.70
  •  361.70
  •  352.00
  •  364.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  382
  •  1.36
  •  499.90
  •  243.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 167.47
  • 10.59
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 113.21
  • 2.22%
  • 2.07

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 45.73%
  • 2.32%
  • 44.73%
  • FII
  • DII
  • Others
  • 2.22%
  • 0.00%
  • 5.00%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.64
  • 4.90
  • 1.21

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.84
  • 3.70
  • -3.66

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.46
  • 6.64
  • -4.75

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.79
  • 16.31
  • 12.41

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.09
  • 2.09
  • 2.09

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.06
  • 8.15
  • 7.46

Quarterly Results

Standalone Figures in Rs. Crores

Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
0
0
0
0
0
0
0
0
0
0
0
0
Expenses
0
0
0
0
0
0
0
0
0
0
0
0
EBITDA
0
0
0
0
0
0
0
0
0
0
0
0
EBIDTM
0%
0%
0%
0%
0%
0%
0%
0%
Other Income
0
0
0
0
0
0
0
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0
0
0
0
0
0
0
0
0
0
0
0
Tax
0
0
0
0
0
0
0
0
0
0
0
0
PAT
0
0
0
0
0
0
0
0
0
0
0
0
PATM
0%
0%
0%
0%
0%
0%
0%
0%
EPS
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

News Update


  • Jenburkt Pharmaceuticals launches antiviral drug 'Favipiravir' to fight COVID-19
    25th Jul 2020, 09:00 AM

    Jenburkt is the second in India to introduce Favipiravir for the treatment of COVID-19

    Read More
  • Jenburkt Pharmaceuticals planning to launch Favipiravir-200 mg tablets
    21st Jul 2020, 11:34 AM

    The Favipiravir-200 mg tablets are recommended for the treatment of mild to moderate COVID-19 patients

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.